|Soo Aleman, MD, PhD, assoc prof is working as hepatologist at department of Infectious Diseases and department of Gastroenterology and Hepatology at Karolinska University Hospital, Sweden. The main focus of her current research is to assess the risks and risk factors for hepatocellular cancer after hepatitis C treatment with sustained virological response in clinical cohort studies. She has also research collaborations about clinical and translational studies about hepatitis B/D/C nationally and internationally. She is currently the main investigator of a genomic study of hepatocellular carcinoma developed after hepatitis C cure in an international network from Europe, USA and Canada.|
|Martti Färkkilä is a professor of gastroenterology at Helsinki University and head of Clinic of Gastroenterology at Helsinki University Hospital (HUH). His main interests are treatment of viral hepatitis, cholestatic liver diseases, especially PSC and inflammatory bowel disease. He has been responsible for the treatment guidelines for HCV and HBV at HUCH. He has supervised 15 PhD students and published more than 220 orginal papers.|
|Jan Albert, MD, PhD, is a professor of Infectious Disease Control at the Karolinska Institute and a Senior Consultant at the Dept of Clinical Microbiology at the Karolinska University Hospital. He has published more than 200 referee-examined scientific papers on different aspects of genetic variation in HIV-1 and HIV-2, including evolution, molecular epidemiology and antiretroviral resistance. He also works other viruses, like enterovirus D68, and is involved in a project on viral discovery. At the clinic, he is involved in molecular diagnostics of virus infections and heads the Microbiology unit of Genomic Medicine Center Karolinska (GMCK) for diagnostics based next-generation sequencing.|
Marianne Alanko Blomé
|Marianne Alanko Blomé, MD, Ph.D, is working as a clinician at the Dept. of Infectious Diseases at the Skåne University Hospital in Malmö. She is the medical supervisor of the Malmö Needle Exchange Program. She is engaged in virological and epidemiological research on transmission of bloodborne viruses among people who inject drugs, with the main focus on HCV.|
|Michael Betts is an Associate Professor of Microbiology at the University of Pennsylvania, Philadelphia, USA. He received is PhD from the University of North Carolina Chapel Hill in 1998, and conducted his postdoctoral training at the University of Texas Southwestern Medical Center and The Vaccine Research Center at the United States National Institutes of Health. Since 2005, his research at the University of Pennsylvania has focused on understanding cellular immune responses in human blood and tissues to a variety of human pathogens, including HIV, Influenza, CMV, and EBV, as well as in the setting of autoimmunity of Type-1 diabetes.|
|Ruth Goodall is a senior statistician at the MRC Clinical Trials Unit at University College London, UK. She has over 20 years of experience working in infectious disease research, focusing on HIV infection. Her work has included a breadth of study types, including Phase I-III clinical trials of treatment strategies, preventative vaccines and immunotherapy, and observational studies focusing on the evolution of drug resistance in adults. For the last 5 years she has led analyses of treatment responses in children and adolescents living with HIV through the EPPICC and CIPHER cohort collaborations.|
|Sofie Hallager, MD, PhD, is a specializing clinician and researcher in the Department of Infectious Diseases at Copenhagen University Hospital, Hvidovre in Copenhagen, Denmark.
Her PhD focused on patients with chronic hepatitis C, with a particular emphasis on patients who develop liver cirrhosis and complications such as liver failure, and hepatocellular carcinoma, and the effect on these events of curing chronic hepatitis C with interferon-based treatment. Currently she is working on research in the occurrence of hepatocellular carcinoma in patients with chronic hepatitis C who have been cured with direct acting antivirals.
|Jeffrey V. Lazarus is on the faculty of CHIP, the WHO Collaborating Centre on HIV and Viral Hepatitis at Rigshospitalet, the University of Copenhagen, and the Barcelona Institute of Global Health (ISGlobal), Hospital Clínic, University of Barcelona. He is Vice-Chair of the Board of the EASL International Liver Foundation and a steering committee member of the European Commission’s two Joint Actions on HIV, hepatitis and other coinfections. His research interests include health systems and policy issues related to HIV and viral hepatitis.|
|Anne-Mette Lebech, MD, Ph.D., DMSc is a senior physician at Department of Infectious Diseases, Copenhagen University Hospital, Rigshospitalet.
She is working as an ID physician taking care of HIV patients.
The main interest of her research is studies on cardiovascular disease in HIV and Women living with HIV.
|Michael Lederman is the Scott R. Inkley Professor of Medicine at Case Western Reserve University School of Medicine and University Hospitals/Case Medical Center where he is also Professor of Pathology, Microbiology/Molecular Biology and Biomedical Ethics. Dr. Lederman is the oldest and most forgetful member of the Laboratory of Interesting Immunology. He received his medical degree from the Mt. Sinai School of Medicine and trained in Internal Medicine at Case Western Reserve University, University Hospitals of Cleveland and the VA Medical Center where he served as chief resident in Medicine. He completed fellowship training in Infectious Diseases, received post-doctoral training in cellular immunology in the laboratory of Dr. Jerrold Ellner and joined the faculty at CWRU in 1980. Dr. Lederman has been engaged in HIV/AIDS research since 1982. He established the Special Immunology Unit (HIV clinic) at CWRU in 1985 and the NIH funded AIDS Clinical Trials Unit at CWRU in 1987. His work focuses on the mechanisms whereby HIV infection induces immune dysfunction and on strategies to correct and prevent it. He is credited as an author of nearly 400 peer reviewed research publications and has read every one of them. He owns two children and lives with his first wife and two dogs. Most recently, he launched a new journal – Pathogens and Immunity - that threatens to make life good for biomedical researchers. He swims (slowly) and plays the piano (badly).|
Ellen Moseholm Larsen
|Ellen Moseholm Larsen, MScH, PhD, is a postdoc at the Department of Infectious Diseases, Copenhagen University Hospital, Hvidovre, Denmark. She is involved in the Danish HIV Birth Cohort, a national cohort investigating the consequences of HIV infection in pregnancy and delivery in women in Denmark. The main interest of her current research is the health and wellbeing of pregnant women living with HIV, mainly focusing on the psychosocial challenges of becoming and being a mother living with HIV.|
|Piotr Nowak MD, PhD is a Director of Clinical HIV research Unit and a Senior Consultant in Infectious Diseases at Karolinska University Hospital, Huddinge Sweden. He is also a team leader at Karolinska Institutet, Department of Medicine: http://ki.se/en/medh/microbiota-inflammation-team
His research is focused on the role of inflammation, microbial translocation and microbiome in chronic viral infections (especially HIV). He is a member of organizing committee of HIV Microbiome Workshops.
|Roger Paredes, MD, PhD, is Chief of Section at the HIV Unit, Hospital Germans Trias i Pujol and Head of the Microbial Genomics Group at the IrsiCaixa AIDS Research Institute, Badalona, Catalonia, Spain.
Roger Paredes obtained an MD, PhD degree in Medicine and Surgery from the Autonomous University of Barcelona (UAB). He specialised in HIV resistance at the Brigham & Women’s Hospital in Boston and Harvard Medical School. His team has demonstrated the clinical utility of HIV-1 deep sequencing in both high- and low-income countries. Dr. Paredes is member of the WHO HIV Drug Resistance Strategy (ResNet) Steering Committee and the International Antiviral Society-USA, which annually produces the IAS-USA list of HIV-1 drug resistance mutations, used worldwide. He has participated in the latest updated of the Rega and Stanford HIVdb algorithms for HIV resistance interpretation and is virologist for the EuroSIDA European cohort. His group is presently leading pioneering research into the role of the gut microbiome in the pathogenesis of HIV infection and chronic inflammation. Dr. Paredes combines his research work at irsiCaixa with a senior medical appointment at the HIV Unit of the Germans Trias i Pujol University Hospital in Badalona, Catalonia, Spain.
Frank Olav Pettersen
|Frank O. Pettersen, PhD, DTM&H, specialist in internal medicine, infectious diseases and medical microbiology and working as a senior consultant in infectious diseases and as head of the Regional Advisory Unit of Imported and Tropical Medicine at the Department of Infectious Diseases at Oslo University Hospital – Ullevål. He holds a PhD in the field of immunopathology in HIV-infection, 20 years of clinical experience from Norway and resource poor settings in the pre-ART era, and is currently also affiliated to the National Advisory Unit in Sexually Transmitted Diseases as an advisor in the implementation of PrEP in Norway.|
|Anastasia Pharris is an Expert in HIV at the European Centre for Disease Prevention and Control (ECDC) in Stockholm, Sweden. She is a nurse with Masters degrees in public health and community health nursing and a PhD in public health. Since 1997 she has worked on clinical and public health aspects of HIV in the USA, Uganda, Zambia, Vietnam, Sweden and, now, at European-level. At ECDC she is responsible for HIV surveillance within the countries of the European Union, an ECDC project on the HIV continuum of care, and has led ECDC scientific guidance project on the prevention of infections among people who inject drugs and men who have sex with men.|
|Dr Matti Ristola is Head of HIV Services at the Division of Infectious Diseases in the Helsinki University Central Hospital in Finland.
Dr Ristola received his MD from the University of Helsinki in 1979. He completed his PhD thesis on neutrophil immunology in 1991. He became a specialist in internal medicine in 1987 and in infectious diseases in 1993.
His research interests include clinical studies on antiretroviral therapy and HIV epidemiology among injecting drug users. He has also studied mycobacterial infections among HIV patients.
|Caroline Sabin, PhD, is Professor of Medical Statistics and Epidemiology at University College London (UCL). Caroline works on the analysis of large observational HIV databases to describing the natural history and clinical epidemiology of HIV infection, identifying prognostic markers and describing outcomes on cART. She established the UK Collaborative HIV Cohort (UK CHIC) Study, was the principal statistician for the D:A:D Study, and jointly leads the POPPY Study, a cohort that aims to study the effects of ageing in HIV infection.|
|Ann Sullivan, Consultant Physician in HIV and Genito-urinary Medicine at the Chelsea and Westminster Hospital, London, and Honorary Lecturer at Imperial College. Previously lead clinician for the John Hunter Clinic, Service Director for Sexual Health and is currently the Directorate Research Committee Chair. Fellow and Trustee on the Board of the British Association of Sexual Health and HIV, Honorary Secretary of the National Audit Group and member of the National Guideline Committee and the Speciality’s National Clinical Standards Unit. Regional Chair of UKCRN Specialty Group for Microbiology and Infectious Diseases. Founding member of the BASHH MSM Special Interest Group and National LGV Surveillance Group. Co-author of European Indicator Condition guided HIV testing guidelines. Member of the Evaluation Advisory Committee for the National HIV prevention programme. Member of the British Association for Sexual Health and HIV, British HIV Association and the European AIDS Clinical Society, International AIDS Society.|